JP2020512019A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512019A5
JP2020512019A5 JP2020503358A JP2020503358A JP2020512019A5 JP 2020512019 A5 JP2020512019 A5 JP 2020512019A5 JP 2020503358 A JP2020503358 A JP 2020503358A JP 2020503358 A JP2020503358 A JP 2020503358A JP 2020512019 A5 JP2020512019 A5 JP 2020512019A5
Authority
JP
Japan
Prior art keywords
car
gene
ucart
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020503358A
Other languages
English (en)
Japanese (ja)
Other versions
JP7314115B2 (ja
JP2020512019A (ja
Filing date
Publication date
Priority claimed from PCT/EP2017/076800 external-priority patent/WO2018073393A2/en
Application filed filed Critical
Priority claimed from PCT/EP2018/058367 external-priority patent/WO2018178377A1/en
Publication of JP2020512019A publication Critical patent/JP2020512019A/ja
Publication of JP2020512019A5 publication Critical patent/JP2020512019A5/ja
Priority to JP2023114120A priority Critical patent/JP7634045B2/ja
Application granted granted Critical
Publication of JP7314115B2 publication Critical patent/JP7314115B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020503358A 2017-03-31 2018-03-30 ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 Active JP7314115B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023114120A JP7634045B2 (ja) 2017-03-31 2023-07-12 ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA201770239 2017-03-31
DKPA201770239 2017-03-31
DKPA201770240 2017-03-31
DKPA201770240 2017-03-31
DKPA201770542 2017-06-30
DKPA201770542 2017-06-30
PCT/EP2017/076800 WO2018073393A2 (en) 2016-10-19 2017-10-19 Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EPPCT/EP2017/076800 2017-10-19
PCT/EP2018/058367 WO2018178377A1 (en) 2017-03-31 2018-03-30 Universal anti-cd22 chimeric antigen receptor engineered immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023114120A Division JP7634045B2 (ja) 2017-03-31 2023-07-12 ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞

Publications (3)

Publication Number Publication Date
JP2020512019A JP2020512019A (ja) 2020-04-23
JP2020512019A5 true JP2020512019A5 (OSRAM) 2021-05-06
JP7314115B2 JP7314115B2 (ja) 2023-07-25

Family

ID=63674321

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020503358A Active JP7314115B2 (ja) 2017-03-31 2018-03-30 ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP2023114120A Active JP7634045B2 (ja) 2017-03-31 2023-07-12 ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023114120A Active JP7634045B2 (ja) 2017-03-31 2023-07-12 ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞

Country Status (14)

Country Link
US (4) US11944643B2 (OSRAM)
EP (3) EP3592379B1 (OSRAM)
JP (2) JP7314115B2 (OSRAM)
KR (1) KR102726269B1 (OSRAM)
CN (1) CN110869046B (OSRAM)
AU (2) AU2018246378A1 (OSRAM)
BR (1) BR112019020203A2 (OSRAM)
CA (1) CA3058268A1 (OSRAM)
DK (1) DK3592379T3 (OSRAM)
ES (1) ES2979232T3 (OSRAM)
IL (1) IL269538B2 (OSRAM)
MX (1) MX2019011475A (OSRAM)
PT (1) PT3592379T (OSRAM)
WO (2) WO2018178378A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020330A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
CN109923110A (zh) 2016-10-05 2019-06-21 小利兰·斯坦福大学托管委员会 苔藓抑素化合物和其制备方法
PT3592379T (pt) * 2017-03-31 2024-05-31 Cellectis Sa Células imunitárias manipuladas universais dotadas de recetor antigénico quimérico anti-cd22
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
EP3774919A4 (en) * 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
JP7589047B2 (ja) * 2018-04-05 2024-11-25 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現する細胞の作製方法および関連組成物
EP3898692A4 (en) 2018-12-19 2022-10-19 The Trustees of the University of Pennsylvania USE OF CD2/5/7 KNOCK-OUT ANTI-CD2/5/7 CHIMERIC ANTIGEN RECEPTOR T-CELLS AGAINST T-CELL LYMPHOMA AND LEUKEMIA
FI3959235T3 (fi) 2019-04-26 2023-09-27 Allogene Therapeutics Inc Rituksimabiresistenttejä kimeerisiä antigeenireseptoreja ja niiden käyttö
EP3972585A4 (en) * 2019-05-21 2023-06-21 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds for enhancement of immunotherapy
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
CN113527507A (zh) * 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 靶向cd22的嵌合抗原受体及其制法和应用
GB202007842D0 (en) * 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
WO2022023529A1 (en) * 2020-07-31 2022-02-03 Cellectis S.A. Dual car-t cells
CN111944850B (zh) * 2020-08-28 2023-03-31 澳门大学 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4294831A1 (en) * 2021-02-16 2023-12-27 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against cd22
KR102829757B1 (ko) * 2021-11-17 2025-07-09 (주)이노베이션바이오 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
EP4452319A1 (en) * 2021-12-22 2024-10-30 Flagship Pioneering Innovations VI, LLC Compositions and methods for delivery of therapeutic agents to acceptor cells
CN118359729A (zh) * 2023-01-19 2024-07-19 武汉昭智生物技术有限公司 一种car分子、包含其的细胞或外泌体及它们的应用
WO2025049961A1 (en) * 2023-09-01 2025-03-06 Cargo Therapeutics, Inc. Anti-cd22 chimeric antigen receptor (car) therapies
WO2025212803A2 (en) * 2024-04-03 2025-10-09 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd22 chimeric antigen receptors
CN119775433B (zh) * 2024-12-09 2025-11-28 吉林大学第一医院 一种细胞膜表达的il-15融合蛋白及其在细胞治疗中的应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6060505A (en) 1996-03-20 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of treating cancer using C-26 modified bryostatin
CA2797661C (en) 1997-04-24 2015-06-16 University Of Washington Targeted gene modification by parvoviral vectors
US6624189B2 (en) 1999-11-30 2003-09-23 The Board Of Trustees Of The Leland Stanford Junior University Byrostatin analogues, synthetic methods and uses
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1047770A1 (zh) 2000-02-24 2003-03-07 Xcyte Therapies, Inc. 细胞的同时刺激与浓缩
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP2737904A3 (en) 2007-02-09 2014-12-17 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
WO2008102199A1 (en) 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
KR101962483B1 (ko) * 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CA3111953C (en) 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
RU2644243C2 (ru) 2011-10-20 2018-02-08 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы к cd22
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126720A2 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
HUE064187T2 (hu) * 2012-05-25 2024-02-28 Cellectis Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására
RU2663725C2 (ru) 2012-09-04 2018-08-08 Селлектис Многоцепочечный химерный антигенный рецептор и его применения
CA2889055C (en) 2012-10-24 2024-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
AU2014273490B2 (en) 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
JP6976058B2 (ja) * 2013-11-22 2021-12-01 セレクティスCellectis 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法
CA2934436A1 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
PT3105317T (pt) 2014-02-14 2019-02-27 Cellectis Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas
EP3693384B1 (en) 2014-03-11 2024-01-24 Cellectis Method for generating t-cells compatible for allogenic transplantation
JP6689202B2 (ja) * 2014-03-19 2020-04-28 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫治療のためのｃｄ１２３特異的キメラ抗原受容体
AU2015248956B2 (en) * 2014-04-14 2020-06-25 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
KR102329836B1 (ko) 2015-01-26 2021-11-19 셀렉티스 암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS)
EP3253866B1 (en) * 2015-02-06 2024-12-04 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
WO2016149578A1 (en) * 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
EP4269601A3 (en) * 2015-03-27 2024-01-10 President and Fellows of Harvard College Modified t cells and methods of making and using the same
JP7396783B2 (ja) 2015-06-09 2023-12-12 エディタス・メディシン、インコーポレイテッド 移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN105958210B (zh) 2016-05-06 2018-10-30 中国科学院国家天文台 Fast望远镜开孔式反射面单元及其开孔方法
CN105968210B (zh) 2016-05-13 2019-05-31 深圳生创精准医疗科技有限公司 靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途
JP7195154B2 (ja) 2016-07-06 2022-12-23 セレクティス 初代免疫細胞における逐次遺伝子編集
WO2018073391A1 (en) * 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073394A1 (en) * 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
PT3592379T (pt) * 2017-03-31 2024-05-31 Cellectis Sa Células imunitárias manipuladas universais dotadas de recetor antigénico quimérico anti-cd22
EP3645036A1 (en) * 2017-06-30 2020-05-06 Cellectis Cellular immunotherapy for repetitive administration
EP4185616A1 (en) * 2020-07-24 2023-05-31 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings

Similar Documents

Publication Publication Date Title
JP2020512019A5 (OSRAM)
JP7157839B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP7527049B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP2023139070A5 (OSRAM)
CN106536563B (zh) 嵌合抗原受体
JP2024105296A5 (OSRAM)
JP2019511222A5 (OSRAM)
CA3062433A1 (en) Bicistronic chimeric antigen receptors and their uses
CN104853765A (zh) 肿瘤特异性t细胞受体
JP2015527070A5 (OSRAM)
WO2019113221A1 (en) Engineered proteins to enhance sensitivity of a cell to il-2
JP2021501567A (ja) Ｙ１８２ｔ突然変異を有するｔ細胞−抗原カプラおよびその方法ならびに使用
JP7747724B2 (ja) マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
TW202102533A (zh) Ｔ細胞受體及其使用方法
CN117264043B (zh) 靶向kras g12v突变多肽的t细胞受体及其用途
WO2021223604A1 (zh) 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
WO2018026018A1 (ja) Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
JP2018518945A (ja) 可溶性キメラインターロイキン−１０受容体およびその療法使用
CN113195535A (zh) 用于连接表达car的免疫细胞与抗原呈递细胞的双特异性多肽及其用途
WO2023051361A1 (zh) 工程化免疫细胞及其用途
EP4502150A1 (en) Engineered immune cell with cd7 gene knock-out and use thereof
WO2023207390A1 (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
WO2018176034A1 (en) Modulators of notch signaling and methods of use thereof
CN115073584A (zh) 一种特异性识别prame抗原肽的tcr及其应用
CN114555815A (zh) T细胞受体及其使用方法